Hematopoietic stem cell (HSC) transplantation treats blood diseases, but donors are scarce and donor age worsens the outcome. With age, HSCs lose their regenerative capacity, shift the balance toward myeloid cells and accumulate epigenetic changes. Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) resets epigenetic age to nearly zero and lengthens telomeres. Yet it remained unclear whether iPSCs could yield HSCs that acquire a full adult blood stem cell identity while keeping young molecular features after transplantation.
The researchers took six iPSC lines from donors aged 18-60, derived from different somatic cells (peripheral blood mononuclear cells, fibroblasts, mesenchymal stem cells). They differentiated them into HSCs using a protocol with spinning embryoid bodies and cytokines. The resulting cells were transplanted into immunodeficient NBSGW mice, which support engraftment of human HSCs without irradiation. After 20 weeks they assessed engraftment, blood composition, DNA methylation profiles, single-cell transcriptomes and telomere length. Then part of the bone marrow from primary recipients was transplanted into secondary mice, and the analyses were repeated after another 20 weeks.
The epigenetic age of the iPSCs, measured by the Horvath clock, was around zero and stayed low after differentiation into HSCs (0.55 years). After the primary transplant, the age of human cells in the mouse bone marrow averaged 1.68 years, and after the secondary transplant 5.28 years, corresponding to aging rates of 2.17 and 7.83 days per day in vivo, respectively. For comparison, cord blood cells aged at a rate of 1.37 days per day. Promoter methylation changed in two phases: first, during in vitro differentiation, pluripotency genes fell silent and hematopoietic regulators switched on; then, after transplantation, a second wave of changes brought the cells closer to primary adult human HSCs. Age-associated CpG sites and methylation entropy stayed stable at every stage. Telomere length in the iPSC-derived HSCs was substantially greater than in primary adult HSCs (median 11,469 versus 8,435 base pairs), and the share of critically short telomeres (<3 thousand base pairs) was 1.33% versus 10.59%.
The work shows that epigenetic aging and the acquisition of HSC identity can be uncoupled: the cells undergo functional maturation yet keep a young epigenome and long telomeres. This challenges the idea that maturity must come with aging and opens a path to transplants that combine adult cell function with a reserve of youth. Unlike the neighboring study on cellular aging, which looked at methylation changes in individual cells, this one demonstrates that the young state holds steady across an entire stem cell population under proliferative stress.
Further studies can test whether the youth persists in longer experiments and in other animal models, including humanized niches. It matters to find out whether the resemblance to primary HSCs reflects cell maturation or the selection of rare clones. Single-cell methylation profiling and clonal tracking will help tell these processes apart. If the young features hold, it will become possible to create universal donor HSCs for treating age-related blood diseases.
The results matter for regenerative medicine, transplantation and gerontology. They lay the groundwork for cell products that combine the functionality of adult HSCs with epigenetic youth.
Next steps include profiling individual stem cells, tracking clones after transplantation and testing in models with a human bone marrow niche. It is also necessary to assess how young epigenetic features affect long-term function and the predisposition to clonal hematopoiesis.
The work speaks directly to an unsolved problem in regenerative medicine: how to obtain functional stem cells that do not carry the burden of donor age. It also touches on the question of which epigenetic changes cause stem cell aging and which are its consequence. The study shows that age-associated methylation can be held at a low level even under intense proliferation, which casts doubt on the inevitability of accumulating epigenetic errors.
The Horvath epigenetic clocks used in the work were calibrated on thousands of human tissue samples and can predict age to within a few years. Here they showed that cells that went through reprogramming and two transplants remain younger than seven years, even though their "real" age, counting the donor and the time in culture, could exceed 60 years.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.